SCHEDULE 13D/A: Activist Investor Galloway Capital Considers Legal Action Against WW International Board Over Bankruptcy Plan

Galloway Capital Partners is considering legal action against WW International's management and board after the rejection of an Equity Committee, arguing the proposed Chapter 11 reorganization plan unfairly wipes out existing shareholders while benefiting lenders and insiders.

Summary

• Galloway Capital Partners, LLC and Bruce Galloway, collectively holding 2.87% of WW International, Inc. (OTCPK: WGHTQ) common stock, have filed an amended Schedule 13D.
• The filing announces Galloway's consideration of legal action against WW International's management, Board of Directors, and lenders.
• This action follows the United States Trustee's rejection of Galloway's request to appoint an official Equity Committee in WW's Chapter 11 bankruptcy cases.
• Galloway asserts that WW's proposed Plan of Reorganization would result in pre-bankruptcy lenders taking 91% of the reorganized company, while existing equity is nearly eliminated and unsecured creditors are paid in full.
• The 9% of shares allocated to existing shareholders in the reorganized company would be further diluted by a Management Incentive Plan for the Company's management and Board members.
• Galloway believes there was no urgent need for bankruptcy, noting that the majority of WW's funded debt is not due until 2028 and 2029, and carries favorable interest rates.
• Despite a revenue decline, WW reported a substantial increase in adjusted EBITDA to $26.9 million in Q1 2025, up 274% from $7.2 million in Q1 2024.
• WW recently announced a pharmacy integration with Eli Lilly and its LillyDirect provider, Gifthealth, to streamline access to Zepbound (tirzepatide) for WeightWatchers Clinic members.
• Galloway estimates WW could generate between $220 million and $250 million of EBITDA this year, suggesting an estimated enterprise value of approximately $3.5 billion based on a conservative 15x EBITDA multiple.
• Galloway proposes an alternative where existing shareholders receive warrants to purchase three shares of the reorganized company's common stock at $1.00 per share, potentially injecting up to $240 million cash into the company.

Sentiment

Score: 3

Explanation: The sentiment is largely negative for existing shareholders due to the proposed bankruptcy plan that would wipe out their equity. While the company shows some operational positives (EBITDA growth, Eli Lilly partnership), the core issue of the filing is the severe adverse impact on current equity holders and the contentious nature of the reorganization process.

Positives

• WW International reported a substantial increase in adjusted EBITDA in the first quarter of 2025 to $26.9 million, representing a 274% increase from $7.2 million in the corresponding period of 2024.
• WeightWatchers announced a strategic pharmacy integration with Eli Lilly and its LillyDirect provider, Gifthealth, expected to streamline access to FDA-approved Zepbound (tirzepatide) for eligible members.
• The company is positioned to be a major player in the weight loss industry, leveraging its storied history and new strategic partnerships.
• Market projections suggest the company's clinical business could grow by 57%, with expected EBITDA generation between $220 million and $250 million this year.
• WW has 3.4 million members, providing a recurring revenue stream and a valuable membership list.

Negatives

• The proposed Plan of Reorganization would result in existing equity being 'all but wiped out', with pre-bankruptcy lenders taking 91% of the reorganized company.
• Shares issued to existing shareholders (9% of the reorganized company) will be further diluted by a Management Incentive Plan for management and Board members.
• The United States Trustee rejected the request to appoint an official Equity Committee, leaving shareholders, particularly individual retail investors (approximately 77.6% of outstanding shares), without adequate representation in the bankruptcy proceedings.
• The proposed plan seeks a nonconsensual injunction of all potential claims against the Company's Board, management, or lenders, effectively removing shareholder recourse.
• Galloway alleges that management and the Board, in collusion with lenders, agreed to the bankruptcy and reorganization plan without shareholder involvement or consent.
• WW International's revenue declined in the first quarter of 2025.

Risks

• Existing shareholders face near-total loss of their investment due to the proposed Chapter 11 Plan of Reorganization.
• The rejection of an Equity Committee means shareholders may not have adequate representation or a voice in the bankruptcy proceedings.
• Potential legal action by Galloway Capital Partners against WW International's management, Board, and lenders introduces litigation risk and uncertainty.
• The proposed Management Incentive Plan will further dilute the already minimal equity stake allocated to existing shareholders in the reorganized company.
• The company's ability to successfully navigate Chapter 11 bankruptcy and implement its Plan of Reorganization is subject to court approval and potential challenges.

Future Outlook

Galloway Capital Partners believes WW International is experiencing a strong turnaround, evidenced by recent financial performance and strategic shifts. They project the company's clinical business to grow by 57% and expect the company to generate between $220 million and $250 million of EBITDA this year, leading to an estimated enterprise value of approximately $3.5 billion. The company's recent partnership with Eli Lilly is expected to streamline access to weight loss medications, positioning WW as a major player in the industry.

Management Comments

• "Weight Watchers is a global brand built over the past 60 years. The Company is at this very time experiencing a strong turnaround, as clearly evidenced by its recent financial performance."
• "Based on market projections, including growth of the Companys clinical business by 57% and the Companys strategic shift, as reflected by its recently announced partnership with Eli Lilly, we believe the Company is expected to generate between $220 million and $250 million of EBITDA this year."
• "Applying a conservative multiple of 15 times EBITDA would result in an estimated enterprise value for the Company of approximately $3.5 billion."
• "We are disappointed with the decision of the United States Trustee to reject our request, on behalf of ourselves and certain other shareholders of Company, to appoint an official Equity Committee on behalf of all of Companys shareholders in the Companys Chapter 11 bankruptcy cases."
• "Clearly, without the support of an Equity Committee, the Companys shareholders will not be able to protect, must less fend for, themselves."
• "Management and the Board, in collusion with the lenders, agreed to the bankruptcy and the related plan of reorganization at the expense of the Companys existing shareholders following backroom negotiations undertaken without shareholder involvement or consent. The Companys shareholders need a seat at the table to negotiate a better deal."
• "We believe there are many constructive ways that the interests of the Companys shareholders can be protected and aligned with the Companys interests. For example, the Company can enable its existing shareholders to have greater participation in the reorganized company by issuing a warrant in respect of each outstanding share to purchase three (3) shares of the common stock of the reorganized company at an exercise price per share of $1.00."

Industry Context

This announcement highlights a significant development in the weight loss industry, particularly concerning the integration of pharmaceutical solutions like GLP-1 drugs (e.g., Zepbound) with traditional weight management programs. WeightWatchers' partnership with Eli Lilly positions it to be a major player in this evolving landscape. The bankruptcy filing and the activist investor's opposition also reflect broader trends in corporate restructuring, where existing equity holders often bear the brunt of financial distress, especially when new, high-value strategic initiatives are emerging.

Corporate Governance

Legal Proceedings

• WW International, Inc. is currently undergoing Chapter 11 bankruptcy cases.
• Galloway Capital Partners is considering pursuing legal action against WW International, Inc., its management, Board of Directors, and the Company's lenders.
• The Company's Plan of Reorganization, if confirmed, would seek a nonconsensual injunction of all potential claims against the Company's Board, management, or lenders from existing shareholders.

Stakeholder Impact

• **Shareholders (especially retail investors):** Face near-total wipeout of their equity under the proposed Plan of Reorganization, with their 9% stake further diluted by a Management Incentive Plan. Their interests are not adequately represented due to the rejection of an Equity Committee.
• **Pre-bankruptcy Lenders:** Stand to gain significantly, taking 91% of the reorganized company, indicating a favorable outcome for them in the restructuring.
• **Unsecured Creditors:** Are expected to be paid in full under the proposed plan.
• **Company Management and Board Members:** Are set to benefit from a Management Incentive Plan, receiving equity or equity-based awards in the reorganized company, which will dilute existing shareholder interests.
• **Employees:** Not directly addressed, but the bankruptcy and restructuring could create uncertainty regarding job security or future compensation structures.
• **Customers/Members:** The company's strategic partnership with Eli Lilly and focus on clinical business could enhance service offerings, but the bankruptcy process itself might cause uncertainty or impact brand perception.

Next Steps

• Galloway Capital Partners is considering pursuing legal action against WW International, Inc., its management, Board of Directors, and lenders.
• Galloway intends to engage the Board and management with respect to the Issuer's performance, operations, management, governance (including potential changes to the Board), conflicted party transactions, capital allocation policies, and strategy and plans.
• Galloway may propose or consider actions described in subparagraphs (a) (j) of Item 4 of Schedule 13D, which include acquiring or disposing of securities, engaging in proxy solicitations, or seeking Board representation.
• The Company's Plan of Reorganization relating to its Chapter 11 bankruptcy will proceed, subject to confirmation by the court.

Key Dates

Recommendation

Keywords

WW International, WeightWatchers, Galloway Capital Partners, Chapter 11 bankruptcy, Plan of Reorganization, Equity Committee, Shareholder rights, Activist investor, EBITDA, Eli Lilly, Zepbound, Weight loss industry, Corporate governance, Legal action, Dilution, Retail investors